These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 27372520)

  • 1. USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs.
    Malapelle U; Morra F; Ilardi G; Visconti R; Merolla F; Cerrato A; Napolitano V; Monaco R; Guggino G; Monaco G; Staibano S; Troncone G; Celetti A
    Lung Cancer; 2017 May; 107():41-49. PubMed ID: 27372520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer.
    Morra F; Merolla F; Criscuolo D; Insabato L; Giannella R; Ilardi G; Cerrato A; Visconti R; Staibano S; Celetti A
    J Exp Clin Cancer Res; 2019 Feb; 38(1):90. PubMed ID: 30786932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma.
    Morra F; Merolla F; D'Abbiero D; Ilardi G; Campione S; Monaco R; Guggino G; Ambrosio F; Staibano S; Cerrato A; Visconti R; Celetti A
    Lung Cancer; 2019 Sep; 135():56-65. PubMed ID: 31447003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
    Morra F; Merolla F; Napolitano V; Ilardi G; Miro C; Paladino S; Staibano S; Cerrato A; Celetti A
    Oncotarget; 2017 May; 8(19):31815-31829. PubMed ID: 28415632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
    Morra F; Luise C; Merolla F; Poser I; Visconti R; Ilardi G; Paladino S; Inuzuka H; Guggino G; Monaco R; Colecchia D; Monaco G; Cerrato A; Chiariello M; Denning K; Claudio PP; Staibano S; Celetti A
    Oncotarget; 2015 May; 6(14):12697-709. PubMed ID: 25885523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma.
    Morra F; Merolla F; Damia G; Ricci F; Varricchio S; Ilardi G; Arenare L; Califano D; Napolitano V; Fruscio R; Melillo RM; Palazzo L; Celetti A
    J Exp Clin Cancer Res; 2022 Aug; 41(1):245. PubMed ID: 35964058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung neuroendocrine tumors: correlation of ubiquitinylation and sumoylation with nucleo-cytosolic partitioning of PTEN.
    Collaud S; Tischler V; Atanassoff A; Wiedl T; Komminoth P; Oehlschlegel C; Weder W; Soltermann A
    BMC Cancer; 2015 Feb; 15():74. PubMed ID: 25884169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.
    Przygodzki RM; Finkelstein SD; Langer JC; Swalsky PA; Fishback N; Bakker A; Guinee DG; Koss M; Travis WD
    Am J Pathol; 1996 May; 148(5):1531-41. PubMed ID: 8623922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The USP7 Inhibitor P5091 Induces Cell Death in Ovarian Cancers with Different P53 Status.
    Wang M; Zhang Y; Wang T; Zhang J; Zhou Z; Sun Y; Wang S; Shi Y; Luan X; Zhang Y; Wang Y; Wang Y; Zou Z; Kang L; Liu H
    Cell Physiol Biochem; 2017; 43(5):1755-1766. PubMed ID: 29049989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USP7 inhibitor P5091 inhibits Wnt signaling and colorectal tumor growth.
    An T; Gong Y; Li X; Kong L; Ma P; Gong L; Zhu H; Yu C; Liu J; Zhou H; Mao B; Li Y
    Biochem Pharmacol; 2017 May; 131():29-39. PubMed ID: 28216017
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapeutic perspectives in CCDC6 deficient lung cancer cells.
    Morra F; Luise C; Visconti R; Staibano S; Merolla F; Ilardi G; Guggino G; Paladino S; Sarnataro D; Franco R; Monaco R; Zitomarino F; Pacelli R; Monaco G; Rocco G; Cerrato A; Linardopoulos S; Muller MT; Celetti A
    Int J Cancer; 2015 May; 136(9):2146-57. PubMed ID: 25302833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP7 is a novel Deubiquitinase sustaining PLK1 protein stability and regulating chromosome alignment in mitosis.
    Peng Y; Liu Y; Gao Y; Yuan B; Qi X; Fu Y; Zhu Q; Cao T; Zhang S; Yin L; Li X
    J Exp Clin Cancer Res; 2019 Nov; 38(1):468. PubMed ID: 31730000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. USP7 and Daxx regulate mitosis progression and taxane sensitivity by affecting stability of Aurora-A kinase.
    Giovinazzi S; Morozov VM; Summers MK; Reinhold WC; Ishov AM
    Cell Death Differ; 2013 May; 20(5):721-31. PubMed ID: 23348568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of thiazole derivatives as novel USP7 inhibitors.
    Chen C; Song J; Wang J; Xu C; Chen C; Gu W; Sun H; Wen X
    Bioorg Med Chem Lett; 2017 Feb; 27(4):845-849. PubMed ID: 28108249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
    Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
    Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deubiquitination of FBP1 by USP7 blocks FBP1-DNMT1 interaction and decreases the sensitivity of pancreatic cancer cells to PARP inhibitors.
    Cheng X; Zhang B; Guo F; Wu H; Jin X
    Mol Oncol; 2022 Apr; 16(7):1591-1607. PubMed ID: 34854226
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.
    Carrà G; Panuzzo C; Torti D; Parvis G; Crivellaro S; Familiari U; Volante M; Morena D; Lingua MF; Brancaccio M; Guerrasio A; Pandolfi PP; Saglio G; Taulli R; Morotti A
    Oncotarget; 2017 May; 8(22):35508-35522. PubMed ID: 28418900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USP7 inhibitor P22077 inhibits neuroblastoma growth via inducing p53-mediated apoptosis.
    Fan YH; Cheng J; Vasudevan SA; Dou J; Zhang H; Patel RH; Ma IT; Rojas Y; Zhao Y; Yu Y; Zhang H; Shohet JM; Nuchtern JG; Kim ES; Yang J
    Cell Death Dis; 2013 Oct; 4(10):e867. PubMed ID: 24136231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting senescent HDF with the USP7 inhibitor P5091 to enhance DFU wound healing through the p53 pathway.
    Zhang S; Meng N; Liu S; Ruan J; Li H; Xu X; Ruan Q; Xie W
    Biochem Biophys Res Commun; 2024 Aug; 722():150149. PubMed ID: 38788355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective USP7 inhibition elicits cancer cell killing through a p53-dependent mechanism.
    Schauer NJ; Liu X; Magin RS; Doherty LM; Chan WC; Ficarro SB; Hu W; Roberts RM; Iacob RE; Stolte B; Giacomelli AO; Perera S; McKay K; Boswell SA; Weisberg EL; Ray A; Chauhan D; Dhe-Paganon S; Anderson KC; Griffin JD; Li J; Hahn WC; Sorger PK; Engen JR; Stegmaier K; Marto JA; Buhrlage SJ
    Sci Rep; 2020 Mar; 10(1):5324. PubMed ID: 32210275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.